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INTRODUCTION
Advances in clinical and molecular imaging techniques have 
led to the recognition of an intermediate state of prostate can-
cer (PCa) in which the disease has extended beyond the pros-
tate, although with limited spread to distant organs. This state 
was first identified and given the terminology, oligometasta-
sis, in 1995 by Hellman and Weichselbaum.1 Further research 
focusing on micro-RNAs involved in the development of met-
astatic disease has shown distinct regulation processes be-
tween oligometastatic and polymetastatic patients, suggesting 
that they are distinct disease entities rather than different points 
in a continuous evolution.2 Moreover, molecular pathological 
analysis with whole-genome sequencing tracing metastatic 
cell clones have suggested that the lethal clone may originate 
from the metastatic lesion, and not from the primary tumor.3 
Thus, oligometastatic disease can be considered a heteroge-
neous disease entity with distinct metastatic phenotypes, 
which may have different prognoses. The clinical implication 
of this hypothesis is that definitive directed treatments for 
oligometastatic PCa, including radical prostatectomy (RP), ra-
diation therapy (RT), and metastasis-directed surgery or abla-
tive therapy, may be utilized for selected patients with a cura-
tive intent.
Emerging data suggest that treatment of the primary tumor 
and metastatic lesions with life-prolonging intent may im-
prove survival for selected patients with metastatic PCa.4-7 Tra-
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With advancements in diagnostic techniques, including molecular and clinical imaging, that directly target cancer cells, oligo-
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and metastatic lesions in an aim to avoid and delay the need for palliative treatments and, ultimately, to achieve survival benefits. 
However, many questions still remain unanswered regarding the understanding of oligometastatic PCa, from its definition to op-
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and/or metastasis-directed therapy using surgery and radiation therapy (RT), can improve survival outcomes with minimal risk 
of adverse effects. Such treatments have been shown to decrease the risks of subsequent palliative interventions and to delay the 
start of androgen-deprivation therapy. Nevertheless, available data are insufficient to draw a reliable conclusion regarding their 
effect on quality of life measures and overall survival. This comprehensive review overviews data from contemporary literature 
that have investigated treatments, including surgery and RT, for patients with oligometastatic PCa, namely pelvic lymph node 
positive disease and limited distant metastases, and summarizes ongoing trials that are evaluating the feasibility of aggressive 
multimodal treatments.
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ditionally, definitive treatments, such as RP or RT, were offered 
with curative intent only in the setting of a localized or locally 
advanced disease. Even minimal disease, such as a single 
positive pelvic lymph node (LN), precluded a definitive thera-
py, and these patients were treated with androgen-depriva-
tion therapy (ADT).8 However, with emerging data that suggest 
treatments targeted at the primary tumor and the metastatic 
lesions may confer survival benefit, research is ongoing to dis-
tinguish subsets of patients who may benefit from aggressive 
treatment. Another advantage of metastasis-directed therapy 
would be a delay in the initiation of ADT. ADT remains a cor-
nerstone of systemic therapy to alleviate cancer-related symp-
toms and to delay cancer progression.8 However, long-term 
use of ADT causes significant psychological and physical side 
effects, and has been suggested to decrease overall survival 
(OS) in some patients.9 In this aspect, the opportunity to per-
haps delay or shorten the duration of ADT by treating oligomet-
astatic PCa with curative intent seems clinically meaningful.
The curative treatment of oligometastatic PCa requires a 
three-tiered approach: 1) local consolidative therapy of the pri-
mary tumor, 2) metastasis-directed therapy, and 3) systemic 
chemohormonal therapy.10 To date, there is no definite evi-
dence-based guideline on the role of these treatments for oligo-
metastatic PCa. We performed a comprehensive review of con-
temporary literature to investigate current evidence regarding 
the feasibility of local treatment of the primary tumor and me-
tastasis-directed therapy for patients with oligometastatic PCa.
RATIONALE FOR LOCAL AND 
METASTASIS-DIRECTED THERAPIES
The rationale of aggressive treatment for oligometastatic PCa 
stands on the hypothesis that such an approach may improve 
OS. Studies have observed that treatment of the primary tumor 
reduces the need for palliative interventions of locally ad-
vanced disease.11,12 Furthermore, early local therapy has been 
found to delay the initiation of systemic therapies, such as ADT, 
which exerts detrimental effects on the quality of life.13
Rationale for local therapy
Several clinically and biologically plausible mechanisms have 
been proposed to explain how aggressive local therapy could 
improve survival in men with oligometastatic PCa. Paget, et 
al.14 introduced the concept of the “seed and soil” theory in 
1889, a widely accepted mechanism in cancer biology. Thereaf-
ter, Kaplan, et al.15 described the perception of a “premetastat-
ic niche” in which nonmalignant bone marrow-derived cells 
are able to sensitize the target tissue for circulating malignant 
cells to be recruited and develop metastatic deposits. In addi-
tion, the primary tumor may reciprocate with nonmalignant 
cells and endocrine factors to control the extent of metastasis. 
This was evident from bone marrow aspirates from patients 
with PCa, in which the development of metastasis was associ-
ated with the presence of circulating tumor cells in bone mar-
row only when the primary tumor was present. Moreover, de-
spite the presence of circulating tumor cells, the risk of developing 
metastasis was imperceptible when the primary tumor was 
absent.16 Cytokine-based influence by the primary tumor was 
presumed for this observation. Recently, Abdollah, et al.17 ob-
served that patients with LN positive PCa performed better 
with RT combined with ADT than ADT alone, supporting this 
hypothesis and providing the rationale of local treatment for 
oligometastatic PCa.
Rationale for metastasis-directed therapy
The feasibility of metastasis-directed therapy in patients with 
oligometastatic PCa is based on the notion that men with low-
volume metastases will exhibit a more favorable outcome from 
less aggressive cancer biology, compared to patients with high-
volume metastases. The concept of eradicating a small num-
ber of metastatic lesions stands on the hypothesis that it may 
yield improved systemic control and survival outcomes for 
oligometastatic PCa. Traditionally, tumor cell seeding had been 
considered a one-way process. However, Kim, et al.18 described 
a concept of ‘‘tumor self-seeding,” which suggests that circu-
lating tumor cells can colonize their own origin of metastatic 
deposits. In other words, the primary tumor may act as a self-
seeding site for circulating tumor cells to be primed and de-
posited at metastatic sites. This lends support to the notion that 
local therapy of the primary tumor or the metastatic deposits 
may inhibit the development of new metastases by altering 
the tumor microenvironment.
This theory has been clinically proven in metastatic settings 
of several cancers, including adrenal metastases from lung 
cancer, liver metastases from colorectal cancer, and lung me-
tastases from various primary tumors.19-21 The improvement in 
OS observed with these metastatic settings means that tumor 
debulking could derive similar benefits in PCa by prolonging 
the duration to a fatal tumor burden. Several related evidence 
also exists regarding metastatic PCa. Patients with low-volume 
metastases tended to progress locally instead of distant, while 
the opposite was observed for men with high-volume metas-
tases.22 Moreover, the site and number of the metastases have 
been observed to affect survival outcomes in patients with 
metastatic PCa, suggesting that this concept may also be ap-
plied to PCa.23 Recently, investigators from the Mayo Clinic 
used stereotactic body radiation therapy (SBRT) for metastatic 
bone lesions of patients with oligometastatic castration-resis-
tant PCa, and reported promising outcomes.24
Another potential advantage of metastasis-directed therapy 
is the delay of initiation of ADT, and the prevention of adverse 
effects associated with castrate levels of serum testosterone. 
The addition of metastasis-directed therapy to systemic treat-
ment could also be an alternative active strategy that could 
eliminate the need or delay chemotherapy targeted at metas-
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tases and ultimately improve OS.25 The Munich registry also 
suggests that patients with metastasis who had RP had better 
survival, although a greater risk of postoperative incontinence 
was reported supposedly due to higher tumor burden often 
close to the sphincter.26 Indeed, such aggressive management 
could be considered for patients who refuse systemic therapy 
with a prioritization on quality of life measures.
For now, there is no consensus on whether treatment of the 
primary tumor with metastasis-directed therapy may confer 
improved survival based on an aggressive approach for oligo-
metastatic PCa and can only be definitively obtained in the 
setting of randomized trials. This obstacle is augmented by the 
lack of a standard definition for oligometastatic PCa, which 
must be properly set out before we can examine the effects of 
therapy in the oligometastatic state.
DEFINITION OF OLIGOMETASTATIC 
DISEASE
The biological definition of oligometastatic PCa remains elu-
sive, and improvements in imaging techniques are shifting 
the paradigm for conventional imaging. No formal cut-off for 
‘‘oligo’’ has been defined, and should only be interpreted as a 
disease state between the presence of intravascular circulat-
ing tumor cells to disseminated metastasis.10,23 Factors to con-
sider when describing oligometastatic disease include the dis-
tinction of synchronous versus metachronous metastases, the 
number and site of lesions, the method of imaging, and wheth-
er the patient is castration-naïve or castration-resistant.27
Numerous studies have proposed different definitions re-
garding the number and sites of metastatic lesions based on 
oncological outcomes (Table 1), and as depicted, the optimal 
cut-off cannot be clearly determined.28-36 Panels adjourned at 
the Advanced Prostate Cancer Consensus Conference 2017, but 
failed to reach a consensus on what constituted the definition 
of synchronous oligometastatic castration-naïve PCa.37 Spe-
cifically, 14% of the panels voted for two metastases, 66% for 
three metastases, and 20% voted for five metastases as a cut-
off. Regarding the site of the metastases, 61% of the panels 
voted for a limited number of bone and/or LNs, 10% voted for 
a limited number of LN metastases, 13% voted for a limited 
number of metastases at any location including visceral dis-
ease, and 10% did not believe that oligometastatic PCa exists 
as a clinically meaningful entity.
In line with advancements in imaging techniques, more pa-
tients considered as M0 on conventional imaging will turn out 
to be oligometastatic. Further research is warranted for a clini-
cally meaningful definition that influences treatment deci-
sions and for the design of future clinical trials.
SURGICAL MANAGEMENT OF 
OLIGOMETASTATIC PROSTATE CANCER
Role of surgery in locally advanced disease
Since the 1990s, a survival benefit with RP has been suggested 
for patients with PCa involving only the pelvic LNs, compared 
to patients who received ADT alone.38,39 Some observational 
studies have suggested an improvement in OS in patients with 
metastatic disease who had previously received RP.40 The mech-
anism underlying this survival advantage is unclear; however, 
according to the concept of oligometastatic disease described 
by Hellman and Weichselbaum,1 such approaches may have 
intervened the disease at a point of limited extent, and have 
controlled the metastatic “niche” to prevent further disease 
progression.
Contemporary literature on oncologic outcomes of patients 
with metastatic PCa has predominantly focused on men who 
received RP with LN dissection and were pathologically prov-
en for LN metastasis. Reported 10-year cancer-specific surviv-
al (CSS) outcomes of these patients range between 70% and 
85%.26,39,41 However, these results were gained with the use of 
multidisciplinary strategies with adjuvant or salvage RT and 
ADT. Such promising results gained attention and encour-
aged the use of RP for selected LN positive patients. The Mu-
nich Cancer Registry was used to compare survival between 
patients with LN positive disease in whom RP was completed 
Table 1. Definitions of Oligometastatic Prostate Cancer
Author (yr) Sample size No. of metastases Sites of metastases Imaging modality
Ahmed, et al. (2013)28 17 ≤5 NR 11C-choline PET/CT, CT, MRI
Berkovic, et al. (2013)29 24 ≤3 Bone or LN Bone scan, 18F-FDG PET/CT, 11C-choline PET/CT
Decaestecker, et al. (2014)30 50 ≤3 Bone or LN 18F-FDG PET/CT, 18F-choline PET/CT
Jereczek-Fossa, et al. (2014)31 69 ≤1 LN 18F-FDG PET/CT, 11C-choline PET/CT, CT
Ost, et al. (2016)32 119 ≤3 Any 18F-FDG PET/CT, 18F-choline PET/CT
Ponti, et al. (2015)33 16 ≤2 LN 11C-choline PET/CT, CT, bone scan
Schick, et al. (2013)34 50 ≤4 NR Bone scan, 18F-choline PET/CT, 11C-acetate PET/CT
Singh, et al. (2004)35 74 ≤5 NR Bone scan
Tabata, et al. (2012)36 35 ≤5 Bone <50% size of vertebral body Bone scan
CT, computed tomography; FDG, fluorodeoxyglucose; LN, lymph node; PET/CT, positron emission tomography with coregistered computed tomography; MRI, 
magnetic resonance imaging; NR, not reported.
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versus men in whom RP was aborted. Notwithstanding the limi-
tation of a retrospective study, the multivariate model adjust-
ed for confounders revealed RP to be independently associat-
ed with the risk of survival.27 These results were replicated by 
Steuber, et al.42 in which RP and positive LN burden were in-
dependently associated with CSS and clinical progression-
free survival (PFS) in patients with LN metastasis who received 
adjuvant ADT. As such, it is important to note that not all pa-
tients with metastatic LNs may benefit from RP. A recent anal-
ysis of patients with LN positive PCa with a previous history of 
RP revealed higher cancer-specific mortality (CSM) in men 
with ≥3 positive LNs, positive surgical margins, Gleason score 
of 7 to 10, and absence of adjuvant RT.43 This highlights the im-
portance of risk stratification in patients with oligometastatic 
PCa, which can aid in identifying those at risk of progression 
who may not be suitable candidates for aggressive multimod-
al treatment.
The benefit of RP can be cautiously inferred from two ran-
domized trials that compared the effects of immediate versus 
delayed ADT with or without RP in patients with LN positive 
PCa.44,45 The main difference between these trials was that the 
Eastern Cooperative Oncology Group (ECOG) 3886 trial in-
cluded patients who received RP, while the ECOG 30846 trial 
included patients who received ADT alone. Both trials did not 
include patients with bone and visceral metastases. While the 
ECOG 30846 trial reported a 10-year OS rate of approximately 
30% with ADT alone, the ECOG 3886 trial showed OS rates of 
45% for RP alone and 64% for ADT in addition to RP.44,45 Al-
though these outcomes are from two studies with completely 
different cohorts, it provides evidence regarding the benefit of 
local treatment with surgery in men with limited LN metastasis.
Reports have shown that RP in patients with LN positive dis-
ease may offer improved oncologic outcomes when used as a 
multimodal strategy with adjuvant RT and ADT. Abdollah, et 
al.17 showed that adjuvant RT to RP with ADT in LN positive 
patients was significantly associated with a lower risk of CSM. 
However, at this time, there is insufficient evidence to set opti-
mal timing and durations of neoadjuvant or adjuvant ADT.
Role of surgery in de novo distant metastatic disease
Several studies have evaluated the role of RP in men with non-
regional LN or bone metastatic PCa (Table 2). Sooriakumaran, 
et al.46 compared outcomes of patients with M1a/M1b disease 
who received RP and extended pelvic LN dissection with pa-
tients with M0 disease. The morbidity rates were comparable, 
with a CSS rate of 89% at 22.8 months in metastatic patients 
receiving RP. Jang, et al.47 retrospectively reviewed oncological 
and peri-operative outcomes between patients with five or 
fewer bone metastases without visceral metastases who re-
ceived robot-assisted RP and those who received ADT alone. 
Robot-assisted RP was a significant predictor of both PFS 
(hazards ratio=0.39) and CSS (hazards ratio=0.26), with com-
parable postoperative complications with previously reported 
RP-treated patients.
The first case-controlled study was performed for patients 
with low-volume M1b PCa, defined as ≤3 bone metastases on 
bone scan. Patients who received cytoreductive prostatectomy 
with extended pelvic LN dissection were compared to a con-
trol group treated with ADT alone. Compared to non-RP group, 
the RP group demonstrated significantly longer clinical PFS 
(39 vs. 28 months), increased time to castration-resistance (40 
vs. 29 months), and improved CSS (96% vs. 84%). However, the 
median CSS period was comparable (47 vs. 41 months). Of 
note, all surgical patients were responsive to ADT, while 32% 
of the control patients did not respond to ADT, suggesting a 
potential selection bias.12
The Surveillance, Epidemiology, and End Results (SEER) data 
were utilized to compare survival outcomes in patients who 
underwent RP or brachytherapy to patients who did not receive 
local therapy.48 Baseline differences in clinicopathological 
features existed between the two groups, with untreated pa-
tients being older and comprising a greater proportion of Glea-
son scores >8 PCa and a smaller proportion of cN0 disease. 
Nevertheless, multivariate competing risk regression analysis 
revealed that patients treated with RP exhibited a 62% de-
creased risk of CSM, compared to controls. Of note, the bene-
fit of RP in regards to improved CSS was observed across all M 
stages.48 The SEER data was revisited by Antwi and Everson49 
using a propensity-score matched analysis to ensure adjust-
ments in baseline cohort differences. In accordance to the pre-
vious study, improved CSS was observed for RP for all M stag-
es. Another population-based study was conducted using the 
Munich Cancer Registry to compare treatment outcomes of pa-
tients with metastatic PCa treated with RP versus non-RP pa-
tients treated with primary ADT or RT. Patients who received 
RP exhibited a significantly higher 5-year OS, compared to 
their counterparts (55% vs. 21%).50 Considering their retrospec-
tive, population-based nature, these results should be cautiously 
interpreted. However, the consistent findings from sophisti-
cated analyses lend support to the notion that RP may be a fea-
sible option for men with de novo distant metastatic PCa.
Considering the protracted natural history of PCa, Satkuna-
sivam, et al.51 linked the SEER database to the Medicare data-
base to account for comorbidities and the use of ADT, which 
may affect survival. The study cohort included patients who re-
ceived RP, intensity modulated RT, conformal RT, and no treat-
ment. The RP group was younger, had lower serum prostate-
specific antigen (PSA) levels, T and N stages, and Gleason score 
PCa than those who did not receive local treatments, and 
were less likely to receive bone radiation or ADT in the 6-month 
period following diagnosis. On multivariable analysis adjust-
ed for ADT, tumor characteristics, comorbidities, and RT to 
bone within 6 months of diagnosis, RP conferred a 52% decrease 
in the risk of CSM.
Two clinical trials are currently evaluating the benefit of sur-
gery in patients with oligometastatic PCa. The first is a non-
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randomized trial comparing CSS and OS outcomes between 
patients receiving RP with extended LN dissection and those 
receiving non-surgical interventions as local treatment 
(NCT02138721).52 The second will determine the safety and fea-
sibility of cytoreductive prostatectomy with adjuvant ADT in 
patients with newly diagnosed metastatic PCa (NCT02458716).53
Role of salvage lymph node dissection in recurrent 
metastatic disease
Salvage LN dissection, if all disease can be removed, can be 
considered for patients with recurrent LN disease following 
primary local therapy. The decision is a challenging process 
and the correct localization of recurred site is essential in the 
clinical decision making. Advanced imaging modalities, such 
as 11C-choline or prostate-specific membrane antigen 
(PSMA) positron emission tomography with coregistered 
computed tomography (PET/CT) may allow selection of opti-
mal candidates for salvage LN dissection.
Several limited case series have evaluated the benefit of sal-
vage LN dissection.54-56 Karnes, et al.54 observed that 57.7% of 
patients showed PSA levels <0.2 ng/mL and that 75% of pa-
tients remained free of systemic progression during the medi-
an follow-up of 20 months. Of note, 83% of the patients had 
received adjuvant ADT following surgery. Suardi, et al.56 ob-
Table 2. Summary of Studies Using RP or Salvage LN Dissection for Oligometastatic Prostate Cancer
Author (yr) Study type
Extent of  
metastasis
No.  
patients
BCR-free 
survival
Progression-free 
survival
Cancer-specific 
survival
Overall 
survival
Radical prostatectomy
Heidenreich,  
  et al. (2015)12
Case-control ≤3 bone, absence  
  of visceral or  
  extensive LN
RP (n=23)
NLT (n=38)
NR NR 96%
84%
p=0.043
91%
79%
p=0.048
Sooriakumaran,  
  et al. (2016)46
Retrospective M1a-M1b RP (n=106) NR NR 89% at  
  23 months
Jang, et al.  
  (2018)47
Retrospective ≤5 bone, absence  
  of visceral lesion RARP (n=38)
ADT (n=41)
NR 40 months
75%
28%
p=0.008
NR NR
Culp, et al.  
  (2014)48
Population-based M1a-M1c
RP (n=245)
BT (n=129)
NLT (n=7811)
NR NR 5 yr
76%
61%
49%
p<0.001
5 yr
67%
53%
23%
p<0.001
Antwi and  
  Everson (2014)49
Population-based M1a-M1c RP (n=222)
BT (n=120)
NLT (n=7516)
NR NR 85%
72%
55%
p<0.001
82%
67%
44%
p<0.001
Gratzke, et al.  
  (2014)50
Population-based M1
RP (n=74)
RT (n=389)
ADT (n=635)
NR NR NA 5 yr
55%
21%
p<0.01
Satkunasivam,  
  et al. (2015)51
Population-based M1
RP (n=47)
IMRT (n=88)
CRT (n=107)
NLT (n=3827)
NR NR 3 yr
79%
82%
49%
46%
3 yr
73%
72%
37%
34%
Salvage lymph node dissection
Karnes, et al.  
  (2015)54
Retrospective N1
52
3 yr
46%
3 yr
47%
3 yr
93%
NR
Jilg, et al.  
  (2012)55
Prospective N1
52
5 yr
9%
5 yr
26%
5 yr
78%
NR
Suardi, et al.  
  (2015)56
Retrospective N1
59
5 yr
29%
5 yr
52%
5 yr
89%
NR
ADT, androgen-deprivation therapy; BCR, biochemical recurrence; CRT, conformal radiation therapy; IMRT, intensity-modulated radiation therapy; LN, lymph 
node; NLT, no local treatment; NR, not reported; RP, radical prostatectomy; RT, radiation therapy.
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served PSA levels <0.2 ng/mL in 59% of men at 40 days, an 
8-year biochemical recurrence (BCR)-free survival rate of 23%, 
and a CSS rate of 81%. Of note, ADT was given if the patient 
had BCR. At a 5-year follow-up, 40% of men were free from 
ADT. Jilg, et al.55 recorded that 46% of patients exhibited a 
complete biochemical response, with an 1-year BCR-free sur-
vival of 71.8% and a 5-year CSS rate of 77.7%. Multivariate anal-
yses from these studies indicated that patients with PSA level 
<4 ng/mL at LN dissection, Gleason score <8, and no involve-
ment of retroperitoneal LNs are better candidates for salvage 
LN dissection.
A systematic review of 12 observational studies regarding 
salvage LN dissection with immediate or deferred ADT has re-
ported a 5-year OS rate of approximately 75% and BCR-free 
survivals ranging between 9% and 22%. Favorable prognosti-
cators following salvage LN dissection were patients with com-
plete PSA response, fewer positive LNs, no involvement of ret-
roperitoneal LNs, and lower preoperative PSA.57 It is important 
to note that these data were derived from observational stud-
ies, and there were no control groups who received ADT alone 
or did not receive salvage LN dissection. Future studies are 
warranted to determine whether these survival outcomes are 
the result of salvage LN dissection or the reflection of the nat-
ural history of oligometastatic recurrent nodal disease.
RADIOTHERAPY IN OLIGOMETASTATIC 
PROATATE CANCER
Modality of radiation therapy
Radiation therapy plays an important role within the treat-
ment landscape of PCa, ranging from up-front treatment for 
localized disease with curative-intent, post-RP adjuvant or 
salvage settings, and as a palliative treatment for men with 
symptomatic metastases.25 Clinical studies on RT used for 
oligometastatic PCa in improving OS or other clinical end-
points have focused on both conventional external beam RT 
(EBRT) and SBRT. Studies have suggested that the mechanism 
of action of SBRT is distinct from EBRT. SBRT can precisely 
target the lesion with an intensified radiation dose while min-
imizing the radiation exposure to adjacent normal tissues.58 
Moreover, the low α/β value of PCa enables hypofractioned 
SBRT to effectively eradicate the target lesions.59 Compared to 
EBRT, which delivers localized cytotoxic effects, SBRT has 
been shown to induce immune responses with the potential for 
additional tumor control.60,61
Role of radiation therapy as a metastasis-directed 
therapy
Three and seven studies have described the roles of EBRT and 
SBRT as metastasis-directed therapies after local treatment, 
respectively (Table 3). Tabata, et al.36 investigated survival out-
comes of men with ≤5 oligometastases or oligo-recurrence of 
bone metastatic PCa treated by EBRT at a median dose of 40 
Gy. The 3-year OS rates for all patients, for patients that received 
a dose of ≥40 Gy, and for those that received <40 Gy were 77%, 
91%, and 50%, respectively. Of note, 87.5% of patients demon-
strated relief of pain at 1 month, and pathological fracture and 
spinal cord compression did not occur at the irradiated sites. 
Rades, et al.62 investigated outcomes of 133 patients with met-
astatic spinal cord compression with ≤3 vertebral lesions de-
tected by CT or MRI and treated with EBRT alone. For patients 
with PCa, the 2-year actuarial local control, defined as recur-
rence of motor deficits in the previously irradiated spinal re-
gion, and OS rates were 80% and 62%, respectively. Schick, et 
al.34 investigated the feasibility of EBRT to treat patients with 
≤five distant and/or regional LNs, bone, and/or lung lesions 
detected by 18F-choline 11C-acetate PET-CT. During the medi-
an followup of 31 months, the authors observed a 3 year BCR-
free survival of 55%, clinical failure-free survival of 59%, and 
an OS of 92%. Of note, neoadjuvant and concomitant ADT 
was given to all but one patient.
Studies addressing RT as a metastasis-directed therapy have 
mainly focused on SBRT. The first studies for SBRT were re-
ported in 2009 by Jereczek-Fossa, et al.,63 who described out-
comes of men with isolated LN metastasis detected by choline 
PET/CT and treated with CyberKnife image-guided SBRT. At 
a mean follow-up of 18.6 months, the local control rate was 
100%. Later, the same methodology was revisited with a larger 
cohort of patients with local recurrence, single LN metastasis, 
and single distant metastasis. The 30-month PFS rate was 
42.6%.64 Similarly, Muacevic, et al.65 prospectively enrolled a 
total of 40 patients with one or two bone metastases and eval-
uated the feasibility of a single fractional CyberKnife robotic 
radiosurgery. Local control, defined as no tumor growth on 
MRI and lack of increased tracer uptake on choline PET-CT, 
was achieved in 95.5% of patients at 2-year follow-up. Of note, 
68% of men were treated with ADT during follow-up. Berkov-
ic, et al.29 reported outcomes of patients who received SBRT at 
a dose of 50 Gy in 10 fractions for ≤3 bone or LN metastases de-
tected with 18F-PET or 11C-acetate PET. The 2-year local con-
trol and clinical progression-free survival was 100% and 42%, 
respectively. 42% of patients started ADT due to progression 
of metastasis and PSA elevation, resulting in a median ADT-
free survival of 38 months. Notably, repeated salvage SBRT for 
metachronous disease was feasible, without significant toxici-
ty. A similar study was performed using SBRT to target liver 
and LN lesions in addition to bone. Local control, defined as 
lack of tumor progression, was achieved in all patients at a 
median followup of 6 months. Among these patients, 53% of 
men reached undetectable serum PSA levels. Of note, 55% of 
men with CRPC exhibited undetectable PSA levels or had 
persistently declining PSA at the time of analysis. No Grade 3 
or late toxicities were observed.27 Decaestecker, et al.30 de-
scribed outcomes for 50 men with ≤3 synchronous LN, bone, 
or liver metastases treated with repeated SBRT at a dose of 50 
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Gy in 10 fractions or 30 Gy in three fractions. The PFS rate at 2 
years was 35%, while the local control rate was 100 months. 
The median delay to ADT was 25 months. Of note, PSA dou-
bling time was a prognosticator of clinical progression and 
ADT-free survival. Lastly, a multi-institutional retrospective 
review evaluated distant PFS of patients with ≤3 metachro-
nous metastatic lesions in which SBRT was delivered to all le-
sions. Distant metastatic lesions were detected using 18F-
PETor choline PET. Herein, a median of 21-month distant PFS 
was reported, with concurrent ADT not having a significant 
benefit in survival.32
In summary, SBRT demonstrates excellent local control, 
with delay in both biochemical and clinical progression. The 
tolerability of SBRT seems to be acceptable, without signifi-
cant grade III toxicity. The use of SBRT to delay ADT confers 
the benefit of maintaining a good quality of life. However, it is 
more likely that SBRT will exert synergistic effects when com-
bined with systemic therapy, which may result in improved 
oncological outcome. In order to define the potential benefits 
of SBRT on long-term oncological outcomes and to establish 
a standard of care, larger studies with homogeneous cohorts 
will be required.
Role of radiation therapy for de novo metastatic disease
Traditionally, positive pelvic LNs or distant metastasis pre-
clude a definitive therapy and are treated with ADT. In an aim 
to improve survival outcomes for this disease setting, attempts 
to combine ADT with RT have been made and reported since 
early 2000 (Table 4).
To date, no randomized controlled trial has compared ADT 
combined with RT to the primary tumor versus ADT alone in 
metastatic PCa. Zagars, et al.66 reported a retrospective analy-
sis on oncologic outcomes of positive LN patients treated by 
RT combined with ADT or ADT alone. The pelvic LNs were 
not included in the RT field. During the median follow-up of 
6.2 years, the RT combined with ADT group exhibited better 
biochemical-free, metastasis-free, and OS outcomes, com-
pared to the ADT alone group. Two randomized controlled 
trials have compared ADT and RT of the prostate versus ADT 
alone in a large group of men with locally advanced or high-
risk localized PCa without distant metastasis. The addition of 
local RT to ADT was associated with reductions in overall 
mortality and CSM. The addition of RT also showed a benefit 
in regards to disease PFS. The adverse effects of RT were ac-
ceptable, and the frequency of serious toxicity was low.67,68 A 
phase III, randomized trial was performed to compare OS and 
metastasis-free survival of patients with radiographic or 
pathologic LN metastasis who received RT with immediate 
ADT or RT alone and ADT at relapse. During the median fol-
low-up of 6.5 years, RT with immediate ADT conferred supe-
rior survival, compared with RT alone and ADT at relapse, 
suggesting the importance of immediate ADT in LN positive 
patients.69 Lastly, the National Cancer Database was used to 
574
Oligometastatic Prostate Cancer
https://doi.org/10.3349/ymj.2018.59.5.567
investigate OS in patients with de novo metastatic PCa receiv-
ing ADT with and without RT on the prostate. On propensity 
score-matched analysis adjusted for baseline clinicopatho-
logical features, the ADT plus RT group demonstrated superi-
or 5-year OS, compared to the ADT alone group (49% vs. 33%).70 
These results provide evidence that aggressive local control of 
the primary tumor may help to eradicate future metastatic 
clones and ultimately improve survival.
SYSTEMIC CHEMOHORMONAL THERAPY
Until recently, ADT was regarded as the standard of care for 
metastatic castration-sensitive PCa. However, evidence from 
recent trials has changed this paradigm and supports the ad-
vantage of systemic chemohormonal therapy in the oligomet-
astatic setting.
STAMPEDE was a randomized, multi-arm, and multi-stage 
trial that recruited patients who were started on first-line ADT 
for de novo metastatic, LN positive, or high-risk locally ad-
vanced disease or previously treated with RP or RT and re-
lapsing with high-risk features. The OS benefit of adding zole-
dronic acid and/or docetaxel to ADT was investigated. Zoledronic 
acid demonstrated no evidence of OS benefits, while docetax-
el chemotherapy conferred improved OS. Based on the results 
from this trial, docetaxel chemotherapy was suggested to be a 
standard of care for chemo-fit men with metastatic disease 
and for men with high-risk non-metastatic PCa with or with-
out RT.71
A systematic review and meta-analysis were performed on 
three eligible trials, including PEACE-1 (NCT01957436),72 LAT-
ITUDE (NCT01715285),73 and STAMPEDE (NCT00268476),74 all 
of which assessed the benefit of adding abiraterone acetate 
plus prednisone/prednisolone (AAP) to ADT in patients with 
metastatic castration-sensitive PCa. The results showed a 38% 
reduction in the risk of death with AAP plus ADT, which trans-
lated into a 14% gain in 3-year OS. Moreover, a 55% reduction 
in the risk of PFS was observed with the addition of AAP, which 
translated to a 28% improvement at 3 years. The results pro-
vided evidence to suggest that AAP with ADT may be an alter-
native option to upfront docetaxel, with potential survival ben-
efits for patients with metastatic castration-sensitive PCa.75
The STAMPEDE and PEACE-1 have evolved the paradigm 
for systemic chemohormonal therapy for oligometastatic PCa, 
and ongoing clinical trials are investigating the synergistic ef-
fect of ADT combined with agents, including abiraterone ace-
tate, enzalutamide, palbociclib isethionate, orteronel, apalu-
tamide, and docetaxel.25
PATIENT SELECTION
Defining the optimal subgroup of patients with oligometasta-
sis for aggressive multimodal therapy is difficult. Generally, 
Table 4. Summary of Studies Using Radiation Therapy for de novo Oligometastatic Prostate Cancer
Author (yr) Study type
Inclusion 
criteria
RT modality No. of patients
Local control  
rate
Progression-free  
survival
Overall 
survival
Zagars, et al. 
  (2001)66
Retrospective Pathologically 
  proven pelvic LN
EBRT to prostate  
  only
RT+ADT (n=72)
ADT alone (n=183)
10 yr
89%
49%
p<0.001
10 yr
85%
56%
p=0.006
10 yr
67%
46%
p=0.008
Lawton, et al. 
  (2005)69
Prospective Pathologically 
  proven LN
EBRT to prostate,  
  abdomen and  
  pelvic LN
RT+ADT (n=98)
RT alone (n=75)
NR 9 yr
10%
4%
p<0.001
9 yr
62%
38%
p=0.23
Widmark, et al. 
  (2009)67
Prospective T3N0M0 Conformal RT RT+ADT (n=436)
ADT alone (n=439)
NR 10 yr PSA recurrence
25.9%
74.7%
p<0.001
10 yr OM
29.6%
39.4%
p=0.004
Warde, et al. 
  (2011)68
Prospective T3 or T4,  
  N0 or Nx
EBRT to pelvis,  
  prostate, seminal  
  vesicle, iliac LN
RT+ADT (n=603)
ADT alone (n=602)
NR NR 7 yr
74%
66%
p=0.033
Rusthoven, et al.
  (2016)70
Retrospective M1 EBRT to prostate  
  or pelvis
RT+ADT (n=538)
ADT (n=5844)
NR NR 8 yr
33%
13%
p<0.001
ADT, androgen-deprivation therapy; EBRT, external beam radiation therapy; LN, lymph node; NR, not reported; OM, overall mortality; PSA, prostate-specific anti-
gen; RT, radiation therapy.
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patients with longer life expectancy, good performance status, 
and few comorbidities would be suitable candidates.76,77 The 
lesion that will be targeted by either surgery or radiotherapy 
should be in a suitable location with a reasonable size so that 
the treatment will not cause detrimental consequences.
IMAGING MODALITY
Current clinical practice is to define the extent of PCa with 
99mTechnetium-methylene diphosphonate (99mTc-MDP) bone 
scan, as well as computed tomography (CT) or magnetic reso-
nance imaging (MRI) to determine the extent of disease in 
men with PCa. These conventional imaging modalities, how-
ever, are limited in terms of their sensitivity for detecting small 
volume sites of PCa and may underestimate the burden of 
disease.78 More specifically, bone scans are estimated to have 
a sensitivity of only 65%, suggesting that a significant amount 
of metastatic disease may go undetected.79 In addition, it is 
known that the majority of LN metastases will not meet estab-
lished size criteria for detection with CT or MRI in those pa-
tients undergoing preoperative staging.80 Due to these limita-
tions, more sensitive imaging tests are needed to accurately 
establish extent of metastatic spread in patients with PCa.
During the past few years, advances in molecular and clini-
cal imaging that directly target cancer cells have conferred a 
more efficient and potentially sensitive approach for PCa im-
aging. The higher yield of detecting lymphatic and/or hema-
togenous metastases at an earlier stage of the disease progres-
sion has resulted with a treatment window for oligometastatic 
disease, and at the same time, is continuously refining the 
definition of oligometastatic PCa.10
Imaging modalities that have recently received attention in-
clude 11C-choline PET/CT, PET/MRI, 18fluorodihydrotestos-
terone PET, 68Ga-labelled PSMA, combined ultra-small super-
paramagnetic particles of iron oxide-enhanced, and 
diffusion-weighted (USPIO-enhanced MRI) and ferumoxytol 
enhanced MRI.10,23,81 Among these, PSMA-targeted imaging 
has recently gained particular interest, as radiotracers target-
ing this cell surface protein have been shown in numerous re-
ports to offer outstanding sensitivity for detecting small-vol-
ume sites of PCa at low PSA levels that are not detectable on 
conventional imaging.82 Furthermore, the addition of MRI has 
the potential to integrate the diagnostic path in cases with 
moderate PSMA tracer accumulation.83 Emerging imaging 
modalities for staging PCa seems promising and will have an 
increasing role in defining oligometastatic PCa and selecting 
the optimal candidates for aggressive treatments.
ONGOING CLINICAL TRIALS
High level evidence needs to be obtained through clinical tri-
als to establish a standard of care. At this point, several active 
clinical trials are investigating the role of multidisciplinary 
treatments for oligometastatic, de novo metastatic, or oligore-
current PCa (Table 5). Most of the trials are evaluating the role 
of radiation therapy, specifically stereotactic radiotherapy. A 
randomized, phase II trial is evaluating the efficacy of metas-
tasis-directed therapy with combined surgery or SBRT in 
oligometastatic recurrence after local therapy versus active 
surveillance (NCT01558427).84 One trial compares toxicity rates 
between normal fractionated versus hypofractionated radia-
tion (NCT02264379).85 
Trials are evaluating the efficacy of local therapy in patients 
with newly diagnosed metastatic or oligorecurrent PCa 
(NCT00268476, NCT01751438, NCT01957436, NCT02138721, 
NCT02454543, and ISRCTN15704862).52,72,74,86-88 The TRoM-
bone trial randomizes 50 men to standard-of-care using ADT 
with or without docetaxel versus standard-of-care plus RP 
with extended pelvic LN dissection (ISRCTN15704862).88
Targeting the anticancer immune response has shown prom-
ise in melanoma, bladder, and lung cancers, suggesting that 
immunotherapies could also be effective in oligometastatic 
PCa. An observational trial is recruiting patients with or with-
out primary treatment managed with SBRT to observe the in-
duction of anti-PCa immunity (NCT01777802).89 Another trial 
is recruiting patients for combined primary treatment of the 
tumor with immunotherapy (NCT02489357).90 There is lack of 
data regarding oligometastatic PCa whether definitive treat-
ment of the primary tumor may improve OS, such as for cyto-
reductive nephrectomy in patients with metastatic renal cell 
carcinoma. One trial is evaluating the efficacy of cytoreductive 
surgery in de novo metastatic PCa (NCT02138721).52
CONCLUDING REMARKS
Since defining the oligometastatic state of PCa, a paradigm 
shift towards more aggressive treatment is gaining support. 
Emerging data suggests treatments targeted at the primary tu-
mor and the metastatic lesions in patients with oligometastat-
ic PCa may prevent or delay the need for palliative treatments 
and confer survival benefit. Among several treatment modali-
ties, SBRT has been demonstrated to be safe and well tolerat-
ed, with excellent local control of bone and LN metastases. 
The biology underlying metastatic progression from the pri-
mary tumor to the metastatic sites, or vice versa, is not com-
pletely understood, and future research is needed to compre-
hend the exact nature of these potentially distinct disease 
entities. Molecular imaging represents a major development 
and an essential tool in the staging of patients with oligometa-
static PCa. In particular, 68Ga PSMA is a promising tracer that 
can accurately assess disease burden, and can be utilized to 
select optimal candidates and tailor treatments. At this time, 
there is no consensus on performing metastasis-directed ther-
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apy for oligometastatic PCa in order to delay ADT and im-
prove survival. However, it can be considered in highly select-
ed patients who demonstrate an indolent course with a limit-
ed disease burden. Systemic therapy with ADT should be 
recommended for patients with a higher disease burden, with 
the addition of docetaxel for chemotherapy-fit patients. Re-
sults from ongoing prospective clinical trials will be needed to 
better define oligometastatic PCa and to clarify the rationale 
of aggressive treatment.
Table 5. Summary of Clinical Trials Investigating Treatment of Oligometastatic Prostate Cancer
Identifier Trial title
Number of 
metastasis
Sites of metastasis
Surgery
NCT0213872152 Local treatment with radical prostatectomy for newly-diagnosed metastatic prostate cancer NR N1, M1
NCT0245871653 Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate 
cancer
NR N1, M1
ISRCTN1570486288 Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a 
randomized controlled feasibility trial (TRoMbone)
≤3 Bone
NCT0245454387 Multicenter, prospective, randomized controlled trial comparing radical prostatectomy plus 
best systemic therapy with best systemic therapy alone in the management of men with 
pauci-metastatic prostate cancer
≤5 Bone, LN
Radiation therapy
NCT0134553991 Phase II study for curative intent treatment for patients with oligometastatic disease at initial 
presentation
≤5 NR
NCT0134555292 Phase II study of stereotactic radiosurgery for patients with oligo-recurrent disease ≤5 NR
NCT0177780289 Observational study of immune responses in prostate, lung, melanoma and breast cancer 
patients following stereotactic body radiotherapy, intensity modulated radiotherapy, or 
brachytherapy
≤3 NR
NCT0185922193 Phase II stereotactic body radiotherapy and stereotactic hypofractionated radiotherapy for 
oligometastatic prostate cancer
NR Any except brain or CNS
NCT0219278894 Phase II study of SBRT as treatment for oligometastases in prostate cancer ≤4 Bone, LN
NCT0226437985 Effectiveness and toxicity of a percutaneous high-dose radiotherapy in patients with oligome-
tastases of prostate carcinoma
≤5 NR
NCT0256369195 Comprehensive stereotactic radiotherapy for oligometastatic prostate cancer: A Phase I/II 
study
≤5 Outside prostate and  
  pelvic LN
NCT0268058796 Phase II randomized observation versus stereotactic ablative radiation for oligometastatic 
prostate cancer (ORIOLE) trial
≤3 Bone, LN
Systemic therapy/combination therapy
NCT0026847674 STAMPEDE: Systemic therapy in advanced or metastatic prostate cancer: Evaluation of drug 
efficacy - androgen suppression-based therapy alone or combined with zoledronic acid, 
docetaxel, prednisolone, celecoxib, abiraterone, enzalutamide and/or radiotherapy, met-
formin and transdermal estradiol in treating patients with locally advanced or metastatic 
prostate cancer
NR N1, M1
NCT0054483097 Androgen deprivation and localized radiotherapy to metastases in patients with oligometa-
static hormone- sensitive prostate cancer
≤5 N1, M1
NCT0155842784 Salvage treatment or active clinical surveillance for oligometastatic prostate cancer: a ran-
domized phase II trial
≤3 N1, M1a/b
NCT0175143886 A prospective, multi-institutional, randomized, phase II trial of best systemic therapy or best 
systemic therapy plus definitive treatment (radiation or surgery) of the primary tumor in 
metastatic (M1) prostate cancer
NR Any except brain
NCT0195743672 A phase III of ADT +/- docetaxel +/- local RT +/- abiraterone acetate in metastatic hormone-
naïve prostate cancer
NR Outside pelvic LN
NCT0248935790 A pilot study of MK-3475 with cryotherapy for men with newly diagnosed oligo-metastatic 
prostate cancer
≤4 Extrapelvis
CNS, central nervous system; LN, lymph node; NR, not reported.
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